TietoEVRY Oyj (FRA:TTEB)

Inozyme Pharma Balance Sheet

Financials in millions EUR. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jun 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	156.8	195.1	219.6	249.7	323.8	252.3
Short-Term Investments	28.1	13.7	17.5	23.6	23.3	35.9
Cash & Short-Term Investments	184.9	208.8	237.1	273.3	347.1	288.2
Cash Growth	-1.18%	-11.94%	-13.25%	-21.26%	20.44%	61.73%
Accounts Receivable	301.9	443.5	537.4	463.4	428.3	411.3
Other Receivables	7.5	21.1	27.3	31.2	23.8	31.6
Receivables	309.4	479.1	579.1	508.2	465.9	458
Inventory	6.1	7.1	8.6	5.6	7.2	4.9
Prepaid Expenses	-	80.9	71.7	58.8	64.8	72.5
Other Current Assets	601.2	-	-	-0.1	-0.1	-0.1
Total Current Assets	1,102	775.9	896.5	845.8	884.9	823.5
Property, Plant & Equipment	95.1	250.1	270.3	280	268	321.5
Long-Term Investments	10.2	27	42.8	29.8	33	33.1
Goodwill	1,408	1,648	1,907	1,847	1,944	1,974
Other Intangible Assets	215.6	313	338.4	333.4	385.1	384.3
Long-Term Accounts Receivable	-	-	-	0.2	2.7	2.9
Long-Term Deferred Tax Assets	24.9	5.4	11.8	14.6	19.1	35.6
Other Long-Term Assets	9.2	34.7	51.3	43.5	50.7	29.5
Total Assets	2,864	3,054	3,518	3,394	3,587	3,605
Accounts Payable	465.5	174.9	206.8	233.9	260.8	189.7
Accrued Expenses	-	320.9	331.9	315.6	338	412.5
Short-Term Debt	-	-	3	3.5	5.1	13.7
Current Portion of Long-Term Debt	13.2	334.9	408.9	107.1	26.4	25.9
Current Portion of Leases	33.6	50.5	50.3	54.1	62.5	72.1
Current Income Taxes Payable	10.5	10.1	20	13.9	18.5	5.5
Current Unearned Revenue	-	49.6	77.3	67.2	73.5	56.3
Other Current Liabilities	373.4	27.8	19.5	21.2	20.5	50.4
Total Current Liabilities	896.2	968.7	1,118	816.5	805.3	826.1
Long-Term Debt	856.6	586.1	559.5	639.4	731.6	885.9
Long-Term Leases	53.2	142.6	161.4	155.9	144	171
Long-Term Unearned Revenue	-	2.4	6.7	16.8	29.2	-
Long-Term Deferred Tax Liabilities	27	24.1	27.5	10.7	9.1	19.8
Other Long-Term Liabilities	8.6	6.2	6.8	6.9	8.2	37.5
Total Liabilities	1,864	1,756	1,906	1,675	1,766	1,979
Common Stock	76.6	76.6	76.6	76.6	76.6	76.6
Additional Paid-In Capital	39.2	38.5	39.4	39.3	41.5	42.1
Retained Earnings	209.5	328.4	570.9	593.7	565.8	438.2
Treasury Stock	-3.9	-1.1	-1.1	-0.3	-0.2	-0.3
Comprehensive Income & Other	679.1	855.7	926.5	1,010	1,137	1,070
Total Common Equity	1,001	1,298	1,612	1,719	1,821	1,626
Shareholders' Equity	1,001	1,298	1,612	1,719	1,821	1,626
Total Liabilities & Equity	2,864	3,054	3,518	3,394	3,587	3,605
Total Debt	956.6	1,114	1,183	960	969.6	1,169
Net Cash (Debt)	-771.7	-905.3	-946	-686.7	-622.5	-880.4
Net Cash Per Share	-6.51	-7.63	-7.97	-5.79	-5.24	-7.42
Filing Date Shares Outstanding	118.4	118.59	118.39	118.41	118.42	118.41
Total Common Shares Outstanding	118.4	118.59	118.39	118.41	118.42	118.41
Working Capital	205.4	-192.8	-221.2	29.3	79.6	-2.6
Book Value Per Share	8.45	10.95	13.62	14.52	15.38	13.73
Tangible Book Value	-622.7	-663.1	-633.4	-460.7	-507.7	-732.5
Tangible Book Value Per Share	-5.26	-5.59	-5.35	-3.89	-4.29	-6.19
Land	-	1.2	1.2	1.2	1.2	1.2
Buildings	-	3.4	3.4	3.8	3.8	3.8
Machinery	-	272.7	339.8	385.7	408.3	398.8
Order Backlog	-	3,261	3,236	3,327	3,513	3,350

Source: S&P Global Market Intelligence. Standard template. Financial Sources.